Cambridge Oncometrix Receive £1 Million in Funding

4 December 2018

SBRI Healthcare have awarded a total of £3.8million in funding to four innovative technology companies focusing on cutting-edge cancer therapies.

Cambridge Oncometrix based at the Innovation Centre on Norwich Research Park have received £1million of this funding to further their development of a non-invasive test that diagnoses prostate cancer early, without the patient having to undergo, sometimes unnecessary, surgery.

Cambridge Oncometrix has developed a non-invasive test that diagnoses prostate cancer early without patients having to undergo a prostate biopsy. Current prostate cancer detection pathway is still very inaccurate and leads to more than 50% of the cases having unnecessary prostate biopsies, where no cancer is found. The Prostate Liquid Biopsy test measures a patient’s semen for prostate-specific chemical elements, which in the presence of cancer, significantly change their concentration.

 Karen Livingstone, National Director of SBRI Healthcare, commented: “The role of SBRI Healthcare is to support technological innovations that tackle specific unmet needs within the NHS. The challenge of enhancing our cancer screening and diagnostic capabilities is a key area of need: by 2035, it is projected that at least 500,000 people will be diagnosed with cancer in the UK each year *.

“Health Secretary, Matt Hancock, has made clear his support for new technology as a way of supporting improved outcomes for patients, and the Prime Minister, Theresa May, has spoken of the need to make a step change in the way we diagnose cancer. SBRI Healthcare has responded to these challenges and the reality that UK cancer survival rates need to improve by focusing on innovations to accelerate the diagnosis of cancer.

Each of the four winning companies was selected on the basis of their potential to deliver improved outcomes for patients and on their potential value to the NHS. The fact that this clutch of projects encompasses technologies including digital pathology, histopathology, liquid biopsy and artificial intelligence, demonstrates the range of innovations available to the NHS. We look forward to working with the inventors of these incredible, ground-breaking technologies to help make their technologies a reality in primary care and within our hospitals.